The GLP-1 Receptor Agonist Liraglutide Increases Myocardial Glucose Oxidation Rates via Indirect Mechanisms and Mitigates Experimental Diabetic Cardiomyopathy
Malak Almutairi, Keshav Gopal, Amanda A. Greenwell, Adrian Young, Robert M. Gill, Hanin Aburasayn, Rami Al Batran, Jadin J. Chahade, Manoj Gandhi, Farah Eaton, Ryan J. Mailloux, John R. Ussher
Topics & Concepts
MedicineLiraglutideDiabetic cardiomyopathyAgonistInternal medicineEndocrinologyGlucagon-like peptide 1 receptorDiabetes mellitusGlucagon-like peptide-1CardiomyopathyCardiologyReceptorType 2 diabetesHeart failureDiabetes Treatment and ManagementCardiovascular Function and Risk FactorsHyperglycemia and glycemic control in critically ill and hospitalized patients